Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia
2015; IOS Press; Volume: 15; Issue: 3 Linguagem: Inglês
10.3233/cbm-150465
ISSN1875-8592
AutoresClaudia Maribel Luna-Aguirre, Margarita L. Martínez‐Fierro, Fermín Mar‐Aguilar, Idalia Garza‐Veloz, Víctor Treviño, Augusto Rojas‐Martínez, José Carlos Jaime‐Pérez, Guadalupe Ismael Malagón‐Santiago, César Homero Gutiérrez‐Aguirre, Óscar González‐Llano, Rosario Salazar‐Riojas, Alfredo Hidalgo‐Miranda, Herminia Guadalupe Martı́nez-Rodrı́guez, David Gómez‐Almaguer, Rocio Ortı́z-López,
Tópico(s)Advanced biosensing and bioanalysis techniques
ResumoBACKGROUND: Acute lymphoblastic leukemia (ALL) is a highly diverse disease characterized by cytogenetic and molecular abnormalities, including altered microRNA (miRNA) expression signatures. AIM: We perform and validate a plasma miRNA expression profiling to identify potential miRNA involved in le ukemogenesis METHODS: MiRNA expression profiling assay was realized in 39 B-ALL and 7 normal control plasma samples using TaqMan Low Density Array (TLDA) plates on Applied Biosystems 7900 HT Fast Real-Time PCR System. MiRNA validation was done for six miRNA differentially expressed by quantitative real-time PCR. RESULTS: Seventy-seven circulating miRNA differentially expressed: hsa-miR-511, -222, and -34a were overexpressed, whereas hsa-miR-199a-3p, -223, -221, and -26a were underexpressed (p values < 0.005 for both sets). According to operating characteristic curve analysis, hsa-miR-511 was the most valuable biomarker for distinguishing B-ALL from normal controls, with an area under curve value of 1 and 100% for sensitivity, and specificity respectively. CONCLUSIONS: Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic targets for patients with B-ALL.
Referência(s)